165 related articles for article (PubMed ID: 30107034)
1. Using Real-World Data to Extrapolate Evidence From Randomized Controlled Trials.
Wang SV; Schneeweiss S; Gagne JJ; Evers T; Gerlinger C; Desai R; Najafzadeh M
Clin Pharmacol Ther; 2019 May; 105(5):1156-1163. PubMed ID: 30107034
[TBL] [Abstract][Full Text] [Related]
2. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
3. Using real world data to support regulatory approval of drugs in rare diseases: A review of opportunities, limitations & a case example.
Gross AM
Curr Probl Cancer; 2021 Aug; 45(4):100769. PubMed ID: 34247834
[TBL] [Abstract][Full Text] [Related]
4. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
Franklin JM; Schneeweiss S
Clin Pharmacol Ther; 2017 Dec; 102(6):924-933. PubMed ID: 28836267
[TBL] [Abstract][Full Text] [Related]
5. Real-world studies no substitute for RCTs in establishing efficacy.
Gerstein HC; McMurray J; Holman RR
Lancet; 2019 Jan; 393(10168):210-211. PubMed ID: 30663582
[No Abstract] [Full Text] [Related]
6. Reproducibility probability in clinical trials.
Shao J; Chow SC
Stat Med; 2002 Jun; 21(12):1727-42. PubMed ID: 12111908
[TBL] [Abstract][Full Text] [Related]
7. Faster drug approval: challenges for safety.
Preziosi P
Expert Opin Drug Saf; 2016 Sep; 15(9):1205-18. PubMed ID: 27308948
[TBL] [Abstract][Full Text] [Related]
8. Postmarketing Modifications of Drug Labels for Cancer Drugs Approved by the US Food and Drug Administration Between 2006 and 2016 With and Without Supporting Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Molto C; Ocana A; Seruga B; Amir E
J Clin Oncol; 2018 Jun; 36(18):1798-1804. PubMed ID: 29641296
[TBL] [Abstract][Full Text] [Related]
9. Lay public's understanding of equipoise and randomisation in randomised controlled trials.
Robinson EJ; Kerr CE; Stevens AJ; Lilford RJ; Braunholtz DA; Edwards SJ; Beck SR; Rowley MG
Health Technol Assess; 2005 Mar; 9(8):1-192, iii-iv. PubMed ID: 15763039
[TBL] [Abstract][Full Text] [Related]
10. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
[TBL] [Abstract][Full Text] [Related]
11. Real-World Evidence and Real-World Data for Evaluating Drug Safety and Effectiveness.
Corrigan-Curay J; Sacks L; Woodcock J
JAMA; 2018 Sep; 320(9):867-868. PubMed ID: 30105359
[No Abstract] [Full Text] [Related]
12. Alternatives to placebo-controlled trials.
Streiner DL
Can J Neurol Sci; 2007 Mar; 34 Suppl 1():S37-41. PubMed ID: 17469680
[TBL] [Abstract][Full Text] [Related]
13. New antirheumatic drugs: any real added value? A critical overview of regulatory criteria for their marketing approval.
Bertele' V; Assisi A; Di Muzio V; Renzo D; Garattini S
Eur J Clin Pharmacol; 2007 Sep; 63(9):879-89. PubMed ID: 17646975
[TBL] [Abstract][Full Text] [Related]
14. Real-world evidence-What is it and does it matter for approval of drugs?
Eaglstein WH
J Am Acad Dermatol; 2018 Aug; 79(2):390-391. PubMed ID: 29410344
[No Abstract] [Full Text] [Related]
15. Series: Pragmatic trials and real world evidence: Paper 1. Introduction.
Zuidgeest MGP; Goetz I; Groenwold RHH; Irving E; van Thiel GJMW; Grobbee DE;
J Clin Epidemiol; 2017 Aug; 88():7-13. PubMed ID: 28549929
[TBL] [Abstract][Full Text] [Related]
16. [Healthcare Research into Anti-VEGF Therapy: Selection and Methodological Precautions].
Ziemssen F; Stahl A; Dimopoulos S
Klin Monbl Augenheilkd; 2017 Dec; 234(12):1483-1492. PubMed ID: 28834972
[TBL] [Abstract][Full Text] [Related]
17. Open-label trials and drug registration: a European regulator's view.
Casteels M; Flamion B
J Thromb Haemost; 2008 Feb; 6(2):232-4. PubMed ID: 18021307
[No Abstract] [Full Text] [Related]
18. Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations.
Hammad TA; Pinheiro SP; Neyarapally GA
Clin Trials; 2011 Oct; 8(5):559-70. PubMed ID: 21878445
[TBL] [Abstract][Full Text] [Related]
19. Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder.
Cipriani A; Barbui C; Rendell J; Geddes JR
Acta Psychiatr Scand; 2014 May; 129(5):328-42. PubMed ID: 24289821
[TBL] [Abstract][Full Text] [Related]
20. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
